Colobreathe® (colistimethate sodium)

This information is only for patients who have been prescribed Colobreathe® (colistimethate sodium) Turbospin® inhaler


Colobreathe® contains colistimethate sodium, a type of antibiotic called a polymyxin.

Colobreathe® is used to control persistent lung infections caused by the bacterium Pseudomonas aeruginosa in adult patients and children aged 6 years and older with cystic fibrosis. Pseudomonas aeruginosa is a very common bacterium that infects nearly all cystic fibrosis patients at some time during their lives. Some people will get this infection whilst very young but for others it will be much later. If this infection is not properly controlled it will cause damage to the lungs.

Colobreathe® works by destroying the bacterial cell membrane, having a lethal effect on them.

For more information please refer to the Patient Information Leaflet.

Colobreathe® (colistimethate sodium) Patient Guide and Instructions for Use

Understanding your Patient Information Leaflet

Within the original packaging of all regulated medicines, you will find an important document called the Patient Information Leaflet. We recommend you read this document carefully and keep it for future reference.

The Patient Information Leaflet gives you key information to help you get the desired results from your medicine. Reading the Patient Information Leaflet is designed to supplement – not replace – discussions with your doctor, pharmacist or other healthcare professional about the medication. 

If for any reason your medicine has not come with this leaflet, you can ask for one from your pharmacist. Patient Information Leaflets are also available to download from the HPRA website.

Go to HRPA website

Get in touch with Teva

We're here to assist patients and healthcare professionals with information about our medicines, devices and services.

Teva Medical Information

Our Medical Information Service can help with enquiries about Teva's medicines, devices and services.

Tel: +44 207 540 7117

They can also provide copies of regulatory documents such as Patient Information Leaflets, or Summary of Product Characteristics. 

Reporting Suspected Side Effects

For patients taking a Teva medicine: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet. By reporting side effects you can help provide more information on the safety of a medicine.

Side effects should be reported to Teva:
Tel: +44 207 540 7117
Online: Side Effect Reporting Form

You can also report side effects via the HPRA website.

Date of preparation: September 2023
Reference: D: CLB-IE-NP-00006 (V1.0) / T: CLB-IE-NP-00007 (V1.0) /M: CLB-IE-NP-00008 (V1.0)